Tatsuhiro Ishida Selected Research

Liposomes (Liposome)

3/2022	A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
1/2022	The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.
1/2022	I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors.
5/2021	Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: A possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies.
10/2020	Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil®) in C26 Tumor-Bearing Immunocompetent Mice.
10/2020	Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
4/2020	A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma.
1/2020	An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
1/2018	Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
1/2018	A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tatsuhiro Ishida Research Topics

Disease

71	Neoplasms (Cancer) 03/2022 - 04/2005
12	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2010
6	Malignant Mesothelioma 04/2020 - 01/2015
4	Stomach Neoplasms (Stomach Cancer) 06/2021 - 01/2018
4	Mesothelioma 04/2020 - 12/2015
4	Hypersensitivity (Allergy) 01/2020 - 05/2013
3	Pancreatic Neoplasms (Pancreatic Cancer) 05/2021 - 09/2017
3	Infections 07/2020 - 05/2013
3	Neoplasm Metastasis (Metastasis) 12/2019 - 04/2005
3	Melanoma (Melanoma, Malignant) 09/2017 - 04/2008
3	Ischemia 03/2006 - 01/2002
2	Neutropenia 01/2022 - 07/2020
2	Ascites 01/2022 - 06/2019
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2021 - 01/2018
2	Autoimmune Diseases (Autoimmune Disease) 05/2021 - 01/2018
2	Experimental Melanoma 01/2021 - 01/2018
2	Anaphylaxis (Anaphylactic Shock) 10/2020 - 01/2020
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2018
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 12/2019
2	Inflammation (Inflammations) 03/2019 - 04/2003
2	Atherosclerosis 01/2019 - 10/2011
2	Bacterial Infections (Bacterial Infection) 01/2018 - 10/2006
2	Colonic Neoplasms (Colon Cancer) 09/2017 - 08/2012
2	Liver Neoplasms (Liver Cancer) 01/2016 - 01/2016
2	Glossitis 01/2014 - 12/2013
2	Stomatitis 01/2014 - 12/2013
2	Lewis Lung Carcinoma 08/2012 - 01/2012
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2012 - 08/2011
2	Fibrosarcoma 08/2011 - 05/2007
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Tumor Lysis Syndrome 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Aseptic Meningitis 11/2021
1	Lupus Nephritis 05/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2021

Drug/Important Bio-Agent (IBA)

49	Liposomes (Liposome)IBA 03/2022 - 03/2002
22	Pharmaceutical PreparationsIBA 01/2022 - 08/2004
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 02/2009
15	Small Interfering RNA (siRNA)IBA 01/2022 - 08/2011
11	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022 - 07/2010
11	Therapeutic UsesIBA 08/2021 - 08/2004
8	Immunoglobulin M (IgM)IBA 03/2022 - 10/2006
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2007
7	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2021 - 03/2002
6	AlbuminsIBA 01/2022 - 10/2016
6	Antineoplastic Agents (Antineoplastics)IBA 08/2021 - 03/2010
5	PlatinumIBA 01/2022 - 02/2009
5	Thymidylate SynthaseIBA 01/2020 - 04/2016
5	Pemetrexed (MTA)FDA Link 11/2016 - 01/2015
4	AntigensIBA 01/2018 - 02/2006
3	Paclitaxel (Taxol)FDA LinkGeneric 06/2021 - 03/2021
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 09/2017
3	liposomal doxorubicin (Doxil)FDA Link 10/2020 - 02/2007
3	RNA (Ribonucleic Acid)IBA 04/2020 - 08/2011
3	human S-nitrosoalbuminIBA 01/2020 - 09/2017
3	LipidsIBA 01/2018 - 07/2010
3	Fluorouracil (Carac)FDA LinkGeneric 01/2017 - 11/2010
3	fasudil (AT 877)IBA 03/2006 - 01/2002
2	Blood Proteins (Serum Proteins)IBA 01/2022 - 04/2005
2	CytokinesIBA 01/2022 - 12/2013
2	LuciferasesIBA 01/2022 - 04/2020
2	VaccinesIBA 01/2022 - 11/2018
2	Human Serum Albumin FDA LinkGeneric 08/2021 - 10/2016
2	Drug CarriersIBA 08/2021 - 08/2012
2	CelluloseIBA 06/2021 - 03/2021
2	Nucleic AcidsIBA 05/2021 - 01/2012
2	AntibodiesIBA 05/2021 - 01/2010
2	Albumin-Bound Paclitaxel FDA Link 05/2021 - 01/2021
2	DFP-10825IBA 01/2020 - 12/2019
2	CholesterolIBA 01/2019 - 12/2015
2	Complement System Proteins (Complement)IBA 01/2019 - 01/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2017 - 10/2016
2	rebamipideIBA 01/2017 - 01/2014
2	Leucovorin (Folinic Acid)FDA Link 01/2014 - 11/2010
2	amsonic acid (DAS)IBA 01/2012 - 02/2009
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2009 - 04/2008
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2007 - 05/2007
2	Matrix Metalloproteinases (MMPs)IBA 09/2007 - 05/2007
1	venetoclaxIBA 01/2022
1	BNT162 VaccineIBA 11/2021
1	COVID-19 VaccinesIBA 11/2021
1	Messenger RNA (mRNA)IBA 11/2021
1	Nanoparticle Drug Delivery SystemIBA 08/2021
1	ProdrugsIBA 08/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 05/2021
1	Albumin ReceptorsIBA 05/2021
1	Cysteine (L-Cysteine)FDA Link 05/2021
1	AcidsIBA 05/2021
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 05/2021
1	Dasatinib (BMS 354825)FDA Link 05/2021

Therapy/Procedure

23	Therapeutics 06/2021 - 11/2010
10	Drug Therapy (Chemotherapy) 01/2022 - 04/2008
6	Injections 11/2018 - 04/2003
4	Oral Administration 01/2021 - 04/2012
4	Intravenous Administration 10/2017 - 01/2013
3	RNAi Therapeutics 01/2020 - 06/2019
2	Transplantation 01/2021 - 08/2005
2	Intravenous Injections 04/2008 - 04/2005
2	Spinal Injections 03/2006 - 08/2004